Safety Analysis
ADVERSE EVENTS, ADVERSE EVENT
All 80 patients in the gefitinib plus chemotherapy group and 75 (92.6%) of the 81 patients in the gefitinib group experienced at least 1 drug-related adverse event. Of these, 32 patients (40.0%) in the gefitinib plus chemotherapy group and 17 patients (21.0%) in the gefitinib group reported grade 3 or worse adverse events (eTable 2 in 